Cargando…
P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621492/ http://dx.doi.org/10.1097/01.HS9.0000890972.83229.41 |
| _version_ | 1784821568197623808 |
|---|---|
| author | Mangasarova, Ya.K. Moiseeva, T.N. Al-Radi, L.S. Margolin, O.V. Gorenkova, L.G. Nesterova, E.S. Bagova, M.O. Fastova, E.A. Abdurashidova, R.R. Sarakaeva, Z.T. Dorokhina, Elena Kravchenko, S.K. Magomedova, A.U. Zvonkov, E.E. |
| author_facet | Mangasarova, Ya.K. Moiseeva, T.N. Al-Radi, L.S. Margolin, O.V. Gorenkova, L.G. Nesterova, E.S. Bagova, M.O. Fastova, E.A. Abdurashidova, R.R. Sarakaeva, Z.T. Dorokhina, Elena Kravchenko, S.K. Magomedova, A.U. Zvonkov, E.E. |
| author_sort | Mangasarova, Ya.K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621492 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96214922022-11-01 P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma. Mangasarova, Ya.K. Moiseeva, T.N. Al-Radi, L.S. Margolin, O.V. Gorenkova, L.G. Nesterova, E.S. Bagova, M.O. Fastova, E.A. Abdurashidova, R.R. Sarakaeva, Z.T. Dorokhina, Elena Kravchenko, S.K. Magomedova, A.U. Zvonkov, E.E. Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621492/ http://dx.doi.org/10.1097/01.HS9.0000890972.83229.41 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Relapsed/Refractory Mangasarova, Ya.K. Moiseeva, T.N. Al-Radi, L.S. Margolin, O.V. Gorenkova, L.G. Nesterova, E.S. Bagova, M.O. Fastova, E.A. Abdurashidova, R.R. Sarakaeva, Z.T. Dorokhina, Elena Kravchenko, S.K. Magomedova, A.U. Zvonkov, E.E. P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma. |
| title | P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma. |
| title_full | P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma. |
| title_fullStr | P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma. |
| title_full_unstemmed | P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma. |
| title_short | P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma. |
| title_sort | p101: combination of immune checkpoint inhibitors with begev in the treatment of patients with relapsed and refractory classical hodgkin’s lymphoma. |
| topic | Relapsed/Refractory |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621492/ http://dx.doi.org/10.1097/01.HS9.0000890972.83229.41 |
| work_keys_str_mv | AT mangasarovayak p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT moiseevatn p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT alradils p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT margolinov p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT gorenkovalg p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT nesterovaes p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT bagovamo p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT fastovaea p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT abdurashidovarr p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT sarakaevazt p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT dorokhinaelena p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT kravchenkosk p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT magomedovaau p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma AT zvonkovee p101combinationofimmunecheckpointinhibitorswithbegevinthetreatmentofpatientswithrelapsedandrefractoryclassicalhodgkinslymphoma |